1. Home
  2. INTT vs IPHA Comparison

INTT vs IPHA Comparison

Compare INTT & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo inTest Corporation

INTT

inTest Corporation

HOLD

Current Price

$18.66

Market Cap

234.0M

Sector

Technology

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.91

Market Cap

189.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INTT
IPHA
Founded
1981
1999
Country
United States
France
Employees
N/A
163
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
234.0M
189.5M
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
INTT
IPHA
Price
$18.66
$1.91
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$13.50
$5.75
AVG Volume (30 Days)
462.9K
128.4K
Earning Date
05-05-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.06
N/A
Revenue
$66,801,000.00
N/A
Revenue This Year
$15.82
$180.36
Revenue Next Year
$9.10
N/A
P/E Ratio
$288.00
N/A
Revenue Growth
66.06
N/A
52 Week Low
$5.81
$1.18
52 Week High
$20.00
$2.63

Technical Indicators

Market Signals
Indicator
INTT
IPHA
Relative Strength Index (RSI) 57.73 54.47
Support Level $7.44 $1.72
Resistance Level $19.91 $2.34
Average True Range (ATR) 1.64 0.21
MACD -0.09 0.05
Stochastic Oscillator 74.68 40.77

Price Performance

Historical Comparison
INTT
IPHA

About INTT inTest Corporation

inTest Corp is a supplier of test and process technology solutions for use in manufacturing and testing across a wide range of markets, including Semi, Auto/EV, Defense/Aerospace, Industrial, Life Sciences, Safety/Security, and Other. The Company has three operating segments, which are also its reportable segments and reporting units: Electronic Test, which generates the majority of its revenue and includes semiconductor test equipment, flying probe, and in-circuit testers; Environmental Technologies, which includes thermal test, process, and storage products; and Process Technologies, which includes induction heating and video imaging products. The Company generates the maximum revenue from the U.S.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: